Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Arnon P. Kater, Jenny Wu, Thomas J. Kipps, +25

Journal of Clinical Oncology

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

Marta Chesi, Geoffrey M. Matthews, Victoria M. Garbitt, +6

Blood

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, +18

Blood

Hematological MalignancyLymphoid NeoplasiaOncologyHealth SciencesMetronomic Therapy +12

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

Simon J. Hogg, Andrea Newbold, Stephin J. Vervoort, +9

Molecular Cancer Therapeutics

Aggressive B-cell LymphomaApoptosisImmunologyCell DeathImmunotherapy +17

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Arnon P. Kater, Thomas J. Kipps, Barbara Eichhorst, +18

Blood

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Meghan C. Thompson, Rosemary Harrup, Catherine C. Coombs, +35

Blood Advances

Hematological MalignancyLymphoid NeoplasiaVenetoclax RetreatmentChronic Lymphocytic LeukemiaPrevious Venetoclax-based Regimen +8

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma

Geoffrey M. Matthews, Marcus Lefebure, Maria Doyle, +9

Cell Death and Disease

Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene

Marcus Lefebure, Richard W. Tothill, Elizabeth Kruse, +23

Nature Communications

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

Arnon P. Kater, Rosemary Harrup, Thomas J. Kipps, +19

Blood

Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study

Rosemary Harrup, Carolyn Owen, James D’Rozario, +10

Blood